Alpha 2.0
Login Register
» Authors » Thomas Egger

Thomas Egger

Explore the profile of Thomas Egger including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 159
Followers 0
Related Specialties
Hematology
Oncology
Infectious Diseases
Top 10 Co-Authors
Philipp Kohler
Christian R Kahlert
Behrouz Mansouri Taleghani
Lorenz Risch
Thomas Pabst
Matthias Schlegel
Daniel Betticher
Pietro Vernazza
Allison McGeer
Stefan P Kuster
Published In
Leuk Lymphoma
Bone Marrow Transplant
Hematol Oncol
BMC Med
Antimicrob Resist Infect Control
Affiliations
Soon will be listed here.
Recent Articles
11.
High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients
Prediletto I, Farag S, Bacher U, Jeker B, Taleghani B, Bregy R, et al.
Bone Marrow Transplant . 2019 Mar; 54(12):1923-1925. PMID: 30890768
No abstract available.
12.
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
Amsler I, Jeker B, Taleghani B, Bacher U, Betticher D, Egger T, et al.
Leuk Lymphoma . 2019 Jan; 60(2):511-514. PMID: 30616438
No abstract available.
13.
Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma
Moor I, Bacher V, Jeker B, Taleghani B, Mueller B, Keller P, et al.
Bone Marrow Transplant . 2018 Jun; 53(12):1599-1602. PMID: 29884856
No abstract available.
14.
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft
Gossi U, Jeker B, Taleghani B, Bacher U, Novak U, Betticher D, et al.
Hematol Oncol . 2018 Jan; 36(2):436-444. PMID: 29363149
Autologous stem cell transplantation (ASCT) as part of the primary therapy in multiple myeloma (MM) is standard practice. In contrast, the role of a second ASCT (ASCT2) and subsequent lenalidomide...
15.
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
Gilli S, Novak U, Taleghani B, Baerlocher G, Leibundgut K, Banz Y, et al.
Ann Hematol . 2016 Dec; 96(3):421-429. PMID: 28011985
BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing...
16.
Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity
Mueller B, Keller S, Seipel K, Taleghani B, Rauch D, Betticher D, et al.
Leuk Lymphoma . 2015 Aug; 57(5):1122-9. PMID: 26294015
Vinorelbine chemotherapy with granulocyte-colony stimulating factor (G-CSF) stimulation is a widely applied non-myelosuppressive mobilization regimen in Switzerland for myeloma patients, but its neurotoxic potential limits its use in patients with...